Sensitive determination of 4-(4-chlorophenyl)-4-hydroxypiperidine a metabolite of haloperidol, in a rat biological sample by HPLC with fluorescence detection after pre-column derivatization using 4-fluoro-7-nitro-2,1,3-benzoxadiazole

Biomedical Chromatography

Volumn 20, Issue 9, 2006, Pages 964-970

  Higashi, Yasuhiko ^a   Nakamura, Shota ^a   Fujii, Youichi ^a  

^a HOKURIKU UNIVERSITY   (Japan)

Author keywords

4 (4 chlorophenyl) 4 hydroxypiperidine; 4 fluoro 7 nitro 2,1,3, benzoxadiazole; Derivatization; Haloperidol; Pharmacokinetic study

Indexed keywords

FLUORESCENCE; METABOLITES; PHARMACOKINETICS; TISSUE;

4-(4-CHLOROPHENYL)-4-HYDROXYPIPERIDINE; 4-FLUORO-7-NITRO-2,1,3,-BENZOXADIAZOLE; BIOLOGICAL SAMPLES; DERIVATIZATIONS; FLUORESCENCE DETECTION; HALOPERIDOL; HPLC-FLUORESCENCE DETECTION; PHARMACOKINETIC STUDIES; PRE-COLUMN DERIVATISATION; TISSUE HOMOGENATES;

RATS;

4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDINE; 4 FLUORO 7 NITRO 2,1,3 BENZOXADIAZOLE; AMOXAPINE; BENZENE; BORIC ACID; BUFFER; DESIPRAMINE; DRUG METABOLITE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; MAPROTILINE; MEXILETINE; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; REAGENT; SERTRALINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CALIBRATION; CONTROLLED STUDY; DERIVATIZATION; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; EXTRACTION; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; RAT; STATISTICAL ANALYSIS; TISSUE HOMOGENATE;

EID: 33748924515     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.630     Document Type: Article

References (21)

1. Ablordeppey SY, Borne RF and Davis WM. Freezing action of a metabolite of haloperidol in frogs. Biochemical Pharmacology 1992; 43: 2181-2187.
2. Arinobu T, Hattori H, Iwai M, Ishii A, Kumazawa T, Suzuki O and Seno H. Liquid chromatographic-mass spectrometric determination of haloperidol and its metabolites in human plasma and urine. Journal of Chromatography B 2002a; 776: 107-113.
3. Arinobu T, Hattori H, Seno H, Ishii A and Suzuki O. Comparison of SSI with APCI as an interface of HPLC-mass spectrometry for analysis of a drug and its metabolites. Journal of American Society of Mass Spectrometry 2002b; 13: 204-208.
4. Bowen WD, Moses EL, Tolentino PJ and Walker JM. Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D-2 receptors. European Journal of Pharmacology 1990; 177: 111-118.
5. Creese I, Burt DR and Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. The Journal of Neuropsychiatry and Clinical Neurosciences 1996; 8: 223-226.
6. Drouot X, Oshino S, Jarraya B, Besret L, Kishima H, Remy P, Dauguet J, Lefaucheur JP, Dolle F, Conde F, Bottlaender M, Peschanski M, Keravel Y, Hantraye P and Palfi S. Functional recovery in a primate model of Parkinson's disease following motor cortex stimulation. Neuron 2004; 44: 769-778.
7. Fang J, Baker GB and Coutts RT. Determination of 4-(4-chlorophenyl)-4-hydroxypiperidine, a metabolite of haloperidol, by gas chromatography with electron-capture detection. Journal of Chromatography B 1996; 682: 283-288.
8. Fang J, McKay G, Song J, Remillrd A, Li X and Midha K. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metabolism and Disposision 2001; 29: 1638-1643.
9. Fornai F, Schluter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL, Pontarelli F, Battaglia G, Pellegrini A, Nicoletti F, Ruggieri S, Paparelli A and Sudhof TC. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proceedings of the National. Academy of Sciences of the United States of America 2005; 102: 3413-3418.
10. Fukushima T, Kawai J, Imai K and Toyo'oka T. Simultaneous determination of d- and L-serine in rat brain microdialysis sample using a column-switching HPLC with fluorimetric detection. Biomedical Chromatography 2004; 18: 813-819.
11. Gorrod JW and Fang J. On the metabolism of haloperidol. Xenobiotica 1993; 23: 495-508.
12. Higashi Y, Kitahara M and Fujii Y. Simultaneous analysis of haloperidol, its three metabolites and two other butyrophenone-type neuroleptics by high performance liquid chromatography with dual ultraviolet detection. Biomedical Chromatography 2006; 20: 166-172.
13. Higashi Y, Matsumura H and Fujii Y. Determination of fluvoxamine in rat plasma by HPLC with pre-column derivatization and fluorescent detection using 4-fluoro-7-nitro-2,1,3-benzoxadiazole. Biomedical Chromatography 2005a; 19: 771-776.
14. Higashi Y, Nakamura S, Matsumura H and Fujii Y. Simultaneous liquid chromatographic assay of amantadine and its four related compounds in phosphate-buffered saline using 4-fluoro-7-nitro-2,1,3-benzoxadiazole as a fluorescent derivatization reagent. Biomedical Chromatography 2005b; 19: 655-662.
15. Nonaka S, Tsunoda M, Imai K and Funatsu T. High-performance liquid chromatographic assay of N(G)-monomethyl-L-arginine, N(G),N(G)-dimethyl-L-arginine, and N(G),N(G)′-dimethyl-L-arginine using 4-fluoro-7-nitro-2,1,3-benzoxadiazole as a fluorescent reagent. Journal of Chromatography A 2005; 1066: 41-45.
16. Otani K, Mihara K, Okada M, Kaneko S and Fukushima Y. Crossover reaction between haloperidol and amoxapine for NMS. British Journal of Psychiatry 1991; 159: 889.
17. Seeman P, Titeler M, Tedesco J, Weinreich P and Sinclair D. Brain receptors for dopamine and neuroleptics. Advances in Biochemical Psychopharmacology 1978; 19: 167-176.
18. Shin JG, Soukhova N and Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metabolism and Disposition 1999; 27: 1078-1084.
19. Snyder SH. Dopamine receptors, neuroleptics, and schizophrenia. American Journal of Psychiatry 1981; 138: 460-464.
20. Yasui-Furukori N, Kondo T, Mihara K, Suzuki A, Inoue Y and Kaneko S. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients. Journal of Clinical Psychopharmacology 2003; 23: 435-440.
21. Yasui-Furukori N, Kondo T, Mihara K, Inoue Y and Kaneko S. Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia. Psychopharmacology 2004; 171: 223-227.